Massive european study aims to unlock secrets of rare kidney disease
NCT ID NCT05927467
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study follows 700 people with Alport syndrome, a rare inherited disease that can lead to kidney failure, hearing loss, and eye problems. Researchers will collect health data and samples over time to map how the disease progresses and to find early markers of kidney decline. The goal is to better understand the disease and prepare for future treatment trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this study could reveal early warning signs of kidney failure in Alport syndrome, helping doctors start treatments sooner and guiding the design of future drug trials.
What could go wrong
This is an observational study, not a treatment trial. It will not directly improve health, and results may take years to produce clear findings.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALPORT SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
RaDiCo Eurbio-Alport
RECRUITINGParis, Île-de-France Region, 75012, France
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••